Small cell lung carcinoma

This Phase 3 study tests whether adding tiragolumab (an experimental immunotherapy) to the standard combination of atezolizumab plus chemotherapy can help people with untreated, widespread small cell lung cancer live longer without their disease worsening. About 123 participants …

Researchers are comparing two doses of chest radiation therapy, 45 Gy and 70 Gy, in people with limited-stage small cell lung cancer. All participants also receive chemotherapy with cisplatin or carboplatin plus etoposide. The trial measures overall survival to see whether the hi…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…

This phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…

This trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…

This trial is investigating whether adding two immunotherapy drugs, nivolumab and ipilimumab, after standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. Even though initial treatment often works well, the cancer frequently returns within …

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants w…

This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This study tested whether avoiding the hippocampus during whole-brain radiation could reduce memory side effects in people with small cell lung cancer. Over 400 patients received either standard whole-brain radiation or a version that spares the hippocampus. The goal was to see i…

This study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…

This phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…

This study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…

This study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. The trial involved 135 newly diagnosed patients. Researchers measured saf…

This study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…

This study tested whether a shorter course of radiation (hypofractionated) given with chemotherapy works as well as the standard longer radiation course for people with limited-stage small cell lung cancer. 860 adults aged 18-70 with early-stage disease took part. The main goal w…

This study tested a pill called abemaciclib in 14 people with certain lung cancers (like small cell lung cancer) that stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors and to check its safety. While the drug targets a specific protein to slow…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth o…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…

This early-phase trial tested the safety and best dose of the immunotherapy drug pembrolizumab when combined with chemotherapy and radiation for people with small cell lung cancer. The goal was to see if adding pembrolizumab helps the immune system fight the cancer more effective…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…

This study looked at 45 patients with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. The goal was to see how long patients went without their cancer getting worse. Because this was a small, single-center review, …

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This study tested a combination of three drugs—nivolumab, ipilimumab, and plinabulin—in 39 adults with recurrent small cell lung cancer that had worsened after initial chemotherapy. The goal was to find the safest dose and see if the combo could slow cancer growth. Results from t…

This study tested a combination of two drugs, anlotinib and penpulimab, in 65 patients with small cell lung cancer whose disease had worsened after initial platinum-based chemotherapy. Anlotinib blocks blood vessel growth to tumors, while penpulimab helps the immune system attack…

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than…

This Phase 3 trial tested whether adding an experimental immunotherapy drug called HLX10 to standard chemotherapy could help people with extensive-stage small cell lung cancer live longer. The study enrolled 585 people who had not received prior treatment. Participants were rando…

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but r…

This early-phase trial tested a four-drug combination (entinostat, atezolizumab, carboplatin, and etoposide) in 3 people with extensive-stage small cell lung cancer that had not been treated before. The goal was to find a safe dose and see if the combination could be given for at…

This early-phase study tested a combination of two drugs, tarlatamab and AMG 404, in 23 adults with small cell lung cancer that had worsened after standard chemotherapy. The main goal was to check safety and find the right dose for future studies. Participants had to be in fairly…

This study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if trilaciclib could protect the bone marrow and immune system from chemotherapy damage, reducing severe side effects like low white b…

This study tested whether adding a drug called trilaciclib to standard chemotherapy could protect the bone marrow and immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their chemo. The main goal…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced small cell lung cancer who are in poor health. The trial included 70 patients with extensive-stage disease and a low performance status (ECOG 2). Researcher…

This study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…

This study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…

This early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…

This study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…

This study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …

This study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…

This study tested a supportive care program for adults aged 60 and older with advanced lung cancer. The program combined physical therapy and relaxation exercises to help improve physical function and emotional wellbeing. Researchers measured how well participants stuck with the …

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…

This study looked at whether a new type of PET/CT scan can help predict how well treatment will work for people with a certain type of lung cancer (limited-stage small cell lung cancer). 33 participants had the scan before starting standard treatment. Researchers then tracked the…

This study looked at whether a simple blood test can monitor lung cancer progression without needing to sample the tumor directly. Researchers checked for genetic changes in the blood of 200 lung cancer patients. The goal was to see if this non-invasive method could track how the…

This study looked at how the drug JDQ443 behaves in people with different levels of liver function. It included 33 adults with small cell lung cancer and mild, moderate, or severe liver problems, plus healthy volunteers. The goal was to measure drug levels in the blood to guide s…